started · updated
Inclisiran outperforms bempedoic acid in LDL cholesterol reduction study
Results from the Victorion-Challenge study, presented at the European Society of Cardiology (ESC) Congress in Munich, indicate that inclisiran is more effective at reducing LDL cholesterol than bempedoic acid in patients with high or very high cardiovascular risk from atherosclerotic cardiovascular disease (Ascvd).
The phase IV, randomized, open-label study found that the inclisiran group experienced a mean LDL-C reduction of 56.31% at day 150, compared to a 15.35% reduction in the bempedoic acid group. Furthermore, 78.2% of patients treated with inclisiran reached their target LDL-C levels, while only 20.3% of those on bempedoic acid achieved the same goal.
Despite the difference in efficacy, the frequency of treatment-related adverse events was similar between the two groups, reported at 63.1% for inclisiran and 59.8% for bempedoic acid.
Entities
European Society of Cardiology · Massimo Grimaldi · Munich · Novartis · Victorion-Challenge
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 4 SOURCES] The bempedoic acid group saw a mean LDL-C reduction of 15.35% at day 150. www.lacronaca24.it · www.adnkronos.com · www.lapresse.it · quotidianodibari.it
- [● 4 SOURCES] The inclisiran group saw a mean LDL-C reduction of 56.31% at day 150. www.lacronaca24.it · www.adnkronos.com · www.lapresse.it · quotidianodibari.it
- [● 4 SOURCES] 78.2% of patients treated with inclisiran reached the LDL-C target compared to 20.3% of those treated with bempedoic acid. www.lacronaca24.it · www.adnkronos.com · www.lapresse.it · quotidianodibari.it
- [● 4 SOURCES] The study is a randomized, open-label, phase IV trial. www.lacronaca24.it · www.adnkronos.com · www.lapresse.it · quotidianodibari.it
- [● 4 SOURCES] The Victorion-Challenge study was presented at the European Society of Cardiology (ESC) Congress in Munich. www.lacronaca24.it · www.adnkronos.com · www.lapresse.it · quotidianodibari.it
- [● 4 SOURCES] Adverse event frequency was comparable between groups (63.1% for inclisiran vs 59.8% for bempedoic acid). www.lacronaca24.it · www.adnkronos.com · www.lapresse.it · quotidianodibari.it
- [● 4 SOURCES] The study compared inclisiran and bempedoic acid (BPA) in patients with high or very high cardiovascular risk. www.lacronaca24.it · www.adnkronos.com · www.lapresse.it · quotidianodibari.it